> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CBER Post-Covid Transition Information
- URL: https://www.fdaweb.com/cber-post-covid-transition-information/
- Published: 2023-06-07T12:00:00.000Z
- Updated: 2026-09-14T18:37:14.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5154633

CBER has released a 6/6 letter to sponsors, applicants, and regulated entities with updated information to assist the recipients to transition back to normal operations in this calendar year following the expiration of the Covid-19 public health emergency. The [letter](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjUjryrxLH%5FAhV8FFkFHSnUDhoQFnoECB0QAQ&url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F136501%2Fdownload&usg=AOvVaw1W6XALV%5FniIemKfR%5FnsFDy) covers information about CBER meetings; FDA guidance; the processing of incoming documents and CBER responses; extension of response due dates for device marketing applications currently on hold; conduct of clinical trials involving medical products; postmarket and compliance activities; how to submit an inquiry for a single patient IND; and emergency use authorization.